Gilead Complera Launch Imminent Following FDA Approval
This article was originally published in The Pink Sheet Daily
Antiretroviral combines Gilead's Truvada with J&J's Edurant for HIV, and is intended as a replacement to the existing triple combination Atripla.
You may also be interested in...
Amgen moves into the chimeric antigen receptor T-cell space in cancer under a complex partnership with Kite Pharma. Gilead, Isis and Janssen agree to multiple deals during and after the holiday season, while scuttled deals return assets or rights to Vanda, AMAG and OncoGenex.
Just weeks after the apparently successful launch of its HIV “quad pill,” Gilead already is talking up a new compound with potential as part of an HIV combination therapy. And in HCV, the company is preparing a new study without partner Bristol-Myers Squibb.
Company is pursuing priority review, eyes FDA approval in mid-2012. If Quad is cleared, newly approved Complera will take back seat.